AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06371118 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mailed self-sampling kit to collect a vaginal sample after opt-in prodecure
Description: Women will initially receive an invitation letter in their home addresses to receive the self-sampling kit, as well as a pre-paid envelope to return the answer to this invitation. If the woman does not return the answer within 10 days, she will be sent a SMS reminder. Only those who respond affirmatively to the question will receive the self-sampling kit.~The steps that follow will be the same as in intervention 1.
Study NCT06371118 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care - screening in a clinical setting
Description: Corresponds to the standard of care. An invitation to attend the conventional cervical cancer screening (clinician-collected cervical sample for HPV test and reflex cytology) will be sent by post to the woman's address.
Study NCT06040008 — intervention group
Intervention type: GENETIC
Intervention: blood collection
Description: * 3 blood collections over a period of 6 weeks~* V0 - Inclusion~* V1 - 3 weeks ± 14 days~* V2 - 3 weeks ± 14 days~* 1 EDTA 4 ml tube, 1 PAXgene RNA tube 2,5 ml and drops of blood from finger-prick are taken at each visit~* Clinical information obtained at each visit
Study NCT05105412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide and Gemcitabine (Dose level 11)
Description: lenalidomide 25 mg/day D1-D14 and gemcitabine 1000 mg/m2 D1, D8
Study NCT05105412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide and Gemcitabine (Dose level 21)
Description: lenalidomide 15 mg/day D1-D14 and gemcitabine 1000 mg/m2 D1, D8
Study NCT05105412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide and Gemcitabine (Dose level 31)
Description: lenalidomide 10 mg/day D1-D14 and gemcitabine 1000 mg/m2 D1, D8
Study NCT05105412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide and Gemcitabine (Dose level 41)
Description: lenalidomide 10 mg/day D1-D14 and gemcitabine 800 mg/m2 D1, D8
Study NCT05616637 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Navicular Drop Test
Description: While participants in sitting position, the navicular tuberosity (NT) will be palpated.The most distal protruding portion of the medial NT will be marked. Participants will be asked to stand with equal weight on both feet. The new distance will be measured. The navicular drop test (NDT) results will then be obtained by comparing the measured values between the sitting and standing positions. Each measurement will be repeated three times and the average of the 3 measurements will be calculated. The expression in mm of the distance between the two marks will be considered the amount of ND. The amount of navicular fall of 10 mm or more will be interpreted as pes planus. Measurements will be made on both extremities. As a result of the measurements, if pes planus is present in a single extremity, that extremity, if it is present in both extremities, the extremity with higher NDT or if it is equal on both sides, the dominant extremity will be tested.
Study NCT05616637 — intervention group
Intervention type: OTHER
Intervention: Lower Extremity Length Measurement
Description: Lower extremity length will be recorded to normalize dynamic balance test data. The person will lie in the supine position. The distance between the umbilicus and the anterior superior of the spina iliaca will be measured in cm with the help of a tape measure. If there is no asymmetry, it will be assumed that there is no rotation in the pelvis, and it will be started to measure the length of the lower extremity. If pelvic asymmetry is detected, the pelvic position will be corrected manually. Then, the most inferior point of the spina iliaca anterior superior and the most distal point of the medial malleolus will be marked and measured and recorded. Lower extremity length and data in 3 different directions will be used in cm. The purpose of using formulas is to easily provide comparisons with other studies using the same type of data. The data obtained from the formula is expressed as a percentage of the length of the limb.
Study NCT05616637 — intervention group
Intervention type: OTHER
Intervention: Y Balance Test
Description: While the individual tries to balance on one bare foot at the midpoint of the assembly, the individual will also be asked to reach as far as possible with the other foot in the anterior, posteromedial and posterolateral directions, touch the tip of the toe, and then immediately return to the starting position without disturbing the balance. The test will be evaluated for 3 repetitions. Situations where the participant will be requested to repeat the test: the foot on the ground passes the reference point or the heel lifts off the ground, perturbations caused by the environment, contact of the foot with the ground, and loss of balance when returning to the starting position. 10 seconds between 3 repetitions during testing will be given. Each participant will be given the right to try 6 times before starting the test in order to eliminate the possible learning parameter. The test will be repeated 3 times in each direction and the closest distance in cm will be recorded.
Study NCT06421883 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus containing probiotic
Description: Patients will be randomized into two groups each group includes 40 patients:~Control group: 40 patients will receive their standard therapy only. Intervention group (probiotic group): 40 patients will receive probiotic 5 billion unit per day with their standard therapy for 3 months.
Study NCT06130423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Music intervention
Description: Music therapy carried out with Music Care
Study NCT06130423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine replacement
Description: NRT: Nicotine Patch, Nicotine Gum
Study NCT06130423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine replacement
Description: NRT: Nicotine Patch, Nicotine Gum
Study NCT06328179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax 100 mg d1，200 mg d2，400 mg d3-14；
Description: VHEA -Induction Phase Regimen/Consolidation therapy after remission
Study NCT05354466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex injection
Description: sugammadex as reversal agent
Study NCT05354466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: neostigmine as a reversal agent
Study NCT06310304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib IR
Description: Tablet
Study NCT06310304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib XR
Description: Tablet
Study NCT05321641 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile phone message reminders.
Description: Utilising mobile messaging service to send reminders to people with epilepsy to take antiseizure medications and sending reminders to primary health facilities to restock anti-seizure medications.
Study NCT05321641 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mobile phone message reminders.
Description: Utilising mobile messaging service to send reminders to people with epilepsy to take antiseizure medications and sending reminders to primary health facilities to restock anti-seizure medications.
Study NCT05060744 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Antacid
Description: The tablets should be kept in the mouth without chewing or swallowing, allowing them to dissolve completely.
Study NCT05060744 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The tablets should be kept in the mouth without chewing or swallowing, allowing them to dissolve completely.
Study NCT05391386 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified bonding technique
Description: adding a layer of compomer adhesive at the molar/tube interface.
Study NCT05327673 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: * quality of life score: FACT-BMT~* decisional conflict scale~* Discreet Choice Experiment questionnaire
Study NCT05758233 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patients undergoing transversalis fascia plane block
Description: The investigators applied a transversalis fascia plane block to the group of patients who had a cesarean section under spinal anesthesia to prevent postoperative pain.
Study NCT05758233 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patients undergoing transversus abdominis plane block
Description: The investigators applied a transversus abdominis plane block to the group of patients who had a cesarean section under spinal anesthesia to prevent postoperative pain.
Study NCT05534386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cancer survivorship care intervention
Description: A one-off face-to-face assessment and personal advice by members of a multidisciplinary team
Study NCT05534386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step-up targeted personalized intervention
Description: To provide a more personalized intervention to the participants, but focusing more on symptom management and weight control.
Study NCT05534386 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: First stage control intervention
Description: A set of skill-based pamphlets will be given.
Study NCT05534386 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Second stage control intervention
Description: Those in the survivorship clinic arm will be asked to follow the advice given by the multidisciplinary team in the initial visit and for those in the control arm will be asked to follow the advices printed in the skill-based self-management pamphlet
Study NCT04909320 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AWARD advice
Description: Ask about smoking history; Warn about the high risk; Advise to quit; Refer smokers to smoking cessation services (with a referral card); Do it again
Study NCT04909320 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AWARD advice
Description: Ask about smoking history; Warn about the high risk; Advise to quit; Refer smokers to smoking cessation services (with a referral card); Do it again
Study NCT04909320 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brief leaflet on health warning and smoking cessation
Description: The contents of the leaflet include (1) highlights of the absolute risk of death due to smoking; (2) the whole list of diseases caused by active and second-hand smoking; (3) ten horrible pictorial warnings of health consequences of smoking and second-hand smoking in one page to maximize the impacts; (4) benefits of SC and (5) simple messages to encourage participants to quit smoking and remind them to call the Department of Health SC hotline 183 3183.
Study NCT04909320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief leaflet on health warning and smoking cessation
Description: The contents of the leaflet include (1) highlights of the absolute risk of death due to smoking; (2) the whole list of diseases caused by active and second-hand smoking; (3) ten horrible pictorial warnings of health consequences of smoking and second-hand smoking in one page to maximize the impacts; (4) benefits of SC and (5) simple messages to encourage participants to quit smoking and remind them to call the Department of Health SC hotline 183 3183.
Study NCT04909320 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Referral card
Description: The contents consist of brief information and highlights of existing SC services, contact methods, motivation information, and strong supporting messages or slogans.
Study NCT04909320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Referral card
Description: The contents consist of brief information and highlights of existing SC services, contact methods, motivation information, and strong supporting messages or slogans.
Study NCT04909320 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-help smoking cessation booklet
Description: The contents include information about the benefits of quitting, smoking and diseases, methods to quit, how to handle withdrawal symptoms, declaration of quitting, etc.
Study NCT04909320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-help smoking cessation booklet
Description: The contents include information about the benefits of quitting, smoking and diseases, methods to quit, how to handle withdrawal symptoms, declaration of quitting, etc.
Study NCT04909320 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive psychological support through 3-people group chat using instant messaging apps
Description: Each IM chat group will consist of a trained SC counselor (HKU staff), a peer supporter (former smoker), and a participant (smoker). The 3-month group chat-based intervention will consist of regular messages and real-time support through group chat. Regular messages will generally include goal setting, health warnings, abstinence support, positive psychological exercises, and encouragement and will be delivered in a tapering style. During the real-time chatting, SC counsellors and peer supporters will provide real-time chat-based support, and peer supporters will share their quitting experience as appropriate.
Study NCT04909320 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: E-messages via SMS
Description: Regular e-messages via SMS at twice per month within 3 months (total 6).
Study NCT04700410 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pure-Vu System
Description: All patients willing to participate will receive a limited bowel preparation (2-days of dietary restrictions + 2x 150ml picoprep) followed by intra-procedural bowel cleansing with the Pure-Vu System.
Study NCT05137288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron , atropine and bupivacaine
Description: Patient received intrathecal hyperbaric bupivacaine ( 10 mg ) ( 2 ml 0.5% ) with morphine 250mic and atropine sulphate 100 micwith total volume = 2.5 ml .~Patient received intrathecal hyperbaric bupivacaine ( 10 mg ) ( 2 ml 0.5% with 0.5 ml normal saline with morphine 250 mic ) with total volume = 2.5 ml with giving 4 mg IV ondansetron before anesthesia ( patients with body weight more than 80 Kg may need additional 4 mg IV ) .
Study NCT04906421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVB-2640
Description: Oral dose, tablet
Study NCT04906421 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral dose, tablet
Study NCT06079567 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Validation of new COMs for FSHD2 patients
Description: Monitoring of commonly used and new COMs in FSHD2 patients
Study NCT05061550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive Durvalumab via intravenous route.
Study NCT05061550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Participants will receive Oleclumab via intravenous route.
Study NCT05061550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monalizumab
Description: Participants will receive Monalizumab via intravenous route.
Study NCT05061550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dato-DXd
Description: Participants will receive datopotamab deruxtecan (Dato-DXd) via intravenous route.
Study NCT05061550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0171
Description: Participants will receive AZD0171 via intravenous route.
Study NCT05061550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin as chemotherapy
Study NCT05061550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin as chemotherapy
Study NCT05061550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed/Cisplatin
Description: Pemetrexed/Cisplatin as chemotherapy
Study NCT05061550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed/Carboplatin
Description: Pemetrexed/Carboplatin as chemotherapy
Study NCT05285618 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Argus II
Description: Participants used the Argus II retinal prosthesis system in both experiments to perform visual perception tasks.
Study NCT05061550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin/Paclitaxel
Description: Carboplatin/Paclitaxel, as chemotherapy
Study NCT05626374 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic Case Management
Description: Usual case management support during 12-week training program
Study NCT05626374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic Case Management plus Distress Tool
Description: Usual case management support during 12-week training program plus daily self-reports of distress using Distress Thermometer tool
Study NCT05061550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volrustomig
Description: Participants will receive Volrustomig via intravenous route.
Study NCT05061550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilvegostomig
Description: Participants will receive Rilvegostomig via intravenous route.
Study NCT06422910 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telerehabilitation
Description: Home exercises will be delivered through a video mobile application. In this application, exercises for knee osteoarthritis will be presented according to their types (stretching, strengthening, etc.). Videos deemed appropriate by the physiotherapist will be added to the exercise prescription and sent to the patients via message. Patients will have the opportunity to remotely access their own exercise prescription with visual, auditory and written commands.~Translated with DeepL.com (free version)
Study NCT06422910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Home exercises will be delivered through a video mobile application. In this application, exercises for knee osteoarthritis will be presented according to their types (stretching, strengthening, etc.). Videos deemed appropriate by the physiotherapist will be added to the exercise prescription and sent to the patients via message. Patients will have the opportunity to remotely access their own exercise prescription with visual, auditory and written commands.~Translated with DeepL.com (free version)
Study NCT04891783 — intervention group
Intervention type: DEVICE
Intervention: ultrasonography
Description: The Carotid US examination will be performed by a radiologist, according to the same protocol in the different participating hospitals. It will include the measurement of cIMT in the common carotid artery and the detection of focal plaques in the extracranial carotid tree following the Mannheimconsensus\[26\]. Plaque is defined as a focal protrusion in the lumen at least cIMT>1.5 mm, protrusion at least 50% greater than the surrounding cIMT, or arterial lumen encroaching >0.5 mm \[26\]. The cIMT will be determined as the average of three measurements in each common carotid artery. The final cIMT is the largest average cIMT (left or right). Patients with carotid plaques will be considered as having very high CV .
Study NCT05486858 — intervention group
Intervention type: OTHER
Intervention: MSK ultrasonograpy
Description: MSK ultrasonography was used to measure the thickness of diaphragm muscle in supine and sitting position and in a relaxed and in a contracted state.
Study NCT05486858 — intervention group
Intervention type: OTHER
Intervention: sitting Functional and Lateral Reach Test
Description: Sitting reach tests were used to measure the stability limits of the trunk in different directions. Functional reach test is for testing the forward direction and lateral reach tests are for testing the right and the left directions.
Study NCT06199531 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GS-100
Description: A single intracerebroventricular (ICV) dose of the study treatment will be administered to patients with confirmed mutations in the NGLY1 gene.
Study NCT05124652 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto Adjusting Prosthesis
Description: Participants will test the auto adjusting prosthesis. The prosthesis will be able to move up to 3 panels built into the socket walls to expand or tighten the socket's fit. The auto adjustments will take place during periods of sitting, standing, or walking. Manual adjustments will also be possible either via the researcher controlling the prosthesis or via the key fob developed in the first aim.
Study NCT05350930 — intervention group
Intervention type: OTHER
Intervention: Assessment of patient satisfaction regarding tele-consultation
Description: Questionnaire completed following the teleconsultation, if applicable.
Study NCT05350930 — intervention group
Intervention type: OTHER
Intervention: Literacy questionnaire
Description: Questionnaire completed during hospitalization for the first chemotherapy cycle
Study NCT05350930 — intervention group
Intervention type: OTHER
Intervention: Collection of socio-demographic characteristics
Description: Questionnaire completed during patient hospitalization for the first chemotherapy cycle
Study NCT05350930 — intervention group
Intervention type: OTHER
Intervention: Assessment of patient knowledge on chemotherapy side effects and support medications
Description: Questionnaire completed during patient hospitalization for the first, second and sixth cycle of chemotherapy
Study NCT05350930 — intervention group
Intervention type: OTHER
Intervention: Assessment of patient satisfaction on pharmaceutical follow-up
Description: Questionnaire completed during patient hospitalization for the sixth chemotherapy cycle
Study NCT04842292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Nebulized heparin 25,000 units every 6 hours
Study NCT04842292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium chloride 0.9% every 6 hours